Sorafenib

Blosozumab (anti-SOST) is an anti-Human sclerostin (SOST) antibody inhibitor. Blosozumab stimulates bone formation and reduces bone resorption.

Blosozumab (anti-SOST) is an anti-Human sclerostin (SOST) antibody inhibitor. Blosozumab stimulates bone formation and reduces bone resorption.

Baker Disposable, Pre-Packed Extraction Columns Polypropylene extraction columns prepacked with sor

InformationDonafenib (Sorafenib D3, Bay 43-9006 D3, CM-4307) is the deuterium labeled Sorafenib. Sorafenib is a multikinase inhibitor IC50s of 6 nM, 15 nM, 20 nM and 22 nM forRaf-1,mVEGFR-2,mVEGFR-3andB-RAF, respectively.TargetsRaf-1 (Cell-free

General description Farnesiferol C is a sesquiterpene coumarin commonly derived from plants like Ferula sinkiangensis , Ferula asafoetida , and Ferula pseudalliacea . Current research indicates that this bioactive metabolite is an inhibitor and

Forerunner patent anti-DSG3 (anti-DSG3) is an anti-desmoglein 3 (Dsg3) monoclonal antibody that depletes desmosomes of Dsg3 and has the potential to be used in research on Pemphigus vulgaris (PV).

Forerunner patent anti-DSG3 (anti-DSG3) is an anti-desmoglein 3 (Dsg3) monoclonal antibody that depletes desmosomes of Dsg3 and has the potential to be used in research on Pemphigus vulgaris (PV).

Forerunner patent anti-DSG3 (anti-DSG3) is an anti-desmoglein 3 (Dsg3) monoclonal antibody that depletes desmosomes of Dsg3 and has the potential to be used in research on Pemphigus vulgaris (PV).

Forerunner patent anti-DSG3 (anti-DSG3) is an anti-desmoglein 3 (Dsg3) monoclonal antibody that depletes desmosomes of Dsg3 and has the potential to be used in research on Pemphigus vulgaris (PV).

InformationGusacitinib (ASN-002) is an orally active and potent dual inhibitor of spleen tyrosine kinase (SYK) and janus kinase (JAK) with IC50 of 5-46 nM. Gusacitinib has anti-cancer activity.

Immunotag™ SOAT1 Antibody*

Immunotag™ SOAT1 Antibody*